ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO836

A Scoring System to Guide Systemic Oral Anticoagulation Among Incident Dialysis Patients with a Preexisting Diagnosis of Atrial Fibrillation/Flutter

Session Information

Category: Dialysis

  • 606 Dialysis: Epidemiology, Outcomes, Clinical Trials - Cardiovascular


  • Albright, Robert C., Mayo Clinic, Rochester, Minnesota, United States
  • Dillon, John J., Mayo Clinic, Rochester, Minnesota, United States
  • Cohen, Dena E., DaVita Clinical Research, Minneapolis, Minnesota, United States
  • Brunelli, Steven M., DaVita Clinical Research, Minneapolis, Minnesota, United States

Among the general population, patients with atrial fibrillation/flutter (Afib) and a CHA2DS2-VASc score ≥2 have high stroke risk and may receive systemic oral anticoagulation (SOA). Utility of CHA2DS2-VASc in patients initiating hemodialysis (HD) with pre-existing Afib is unclear.


We considered adult Medicare enrollees who initiated HD at a large US dialysis organization in 2010-2011 with pre-existing Afib, determined from claims. Exposures were risk scores and SOA, based on a prescription fill during the first 3 months of HD. Outcome (stroke/transient ischemic attack [TIA]) was considered from HD start until censoring or study end (Dec 2012), and compared using intention-to-treat principles and Cox proportional hazard models. An HD-specific risk score was developed using a logistic model fit by stepwise elimination of non-contributing variables (p>0.1). Positive outcomes were SOA and no stroke/TIA, and no SOA and stroke/TIA; negative outcomes were the converse.


Among 2742 patients initiating HD with Afib, no association was observed between SOA and risk of stroke/TIA across CHA2DS2-VASc categories. Female sex, Hispanic race, use of a central venous catheter, congestive heart failure, and diabetes defined an HD-specific risk score. In the top quartile of this score, SOA (vs. no SOA) was associated, at near statistical significance, with a lower point estimate for risk of stroke/TIA.


We developed a risk score that, unlike CHA2DS2-VASc, may identify incident HD patients with Afib who will benefit from SOA. Further work is needed to refine and validate this HD-specific score.


  • Commercial Support